Introduction
Epidermal growth factor receptor (EGFR) has been thought to be a significant factor in the development and growth of many types of tumors. The pathway mediated by the EGFR is very important in modulating cell proliferation, cell survival, migration and differentiation (Wells, 1999; Yarden, 2001) . EGFR plays an important role in extensive crosstalk among multiple signaling pathways and regulation of cell function (Yarden, 2001; Gschwind et al., 2001) . Phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) is a highly potent tumor promoter and is widely used for the study of the mechanism of tumor promotion. Previous studies have demonstrated that activator protein-1 (AP-1) is a key transcription factor in the tumor promotion induced by different tumor promoters, including TPA, epidermal growth factor (EGF), UV radiation and other tumor promoters (Huang et al., 1997a (Huang et al., , 1999a Young et al., 1999) . Signal transduction pathways leading to AP-1 activation seem to be a common mechanism for these diverse types of tumor promoters (Huang et al., 1997a; Shaulian and Karin, 2001; Jochum et al., 2001) . TPAinduced tumor promotion is thought to be related to the PKC/MAPK/AP-1 pathway, although the molecular mechanism is not fully understood (Blumberg, 1991; Huang et al., 1997b, c) . Several recent reports show that EGFR was phosphorylated in TPA-promoted skin tumors from SENCAR mice and in TPA-treated cultured cells (Xian et al., 1995; Prenzel et al., 1999) , suggesting that EGFR may be involved in TPA-induced tumor promotion. Therefore, the present study was aimed at determining if the EGFR and its tyrosine kinase are necessary for AP-1 transactivation induced by TPA or EGF. A well-characterized murine fibroblast cell line B82, cells devoid of EGFR, and its wide-type EGFR stable transfectant, B82L, as well as the kinasedeficient EGFR stable transfectant, B82M721, were used to investigate the role of EGFR and tyrosine kinase of EGFR in EGF-and TPA-induced AP-1 activation.
Results

TPA or EGF induces AP-1 activity in the cells expressing wild-type EGFR, but not in the cells devoid of EGFR
To determine whether EGFR plays a role in TPAinduced AP-1 activation, we used a well-characterized mouse fibroblast cell line B82, which is devoid of endogenous EGFR, and its derived cell lines, B82L and B82M721, which are B82 cells stably expressing wildtype human EGFR and kinase-deficient human EGFR, respectively (Chen et al., 1987) . The AP-1-luciferase reporter stable transfectants were established as described in our previous reports (Huang et al., 1996a) . Exposure of these transfectants to either TPA or EGF resulted in transactivation of AP-1 in B82L AP-1 mass1, but not in B82 AP-1 mass1 (Figure 1 ). To be sure of the EGFR-dependent manner of AP-1 induction by TPA and EGF, we performed a time course and dose response study. The results further confirmed the above findings (Figures 2a-d) . Similar results were also observed in several mass cultures and cloned cells (Figures 5a and b) . These results provide direct evidence that EGFR is not only necessary for AP-1 induction by EGF, but is also required for TPA-induced AP-1 activation. These data are consistent with previous findings that the specific EGFR antibody or inhibitors can block TPA-induced AP-1 DNA-binding activity .
Tyrosine kinase of EGFR is not required for TPAinduced AP-1 activation. The EGFR has intrinsic protein tyrosine kinase activity, which is responsible for many of the pleotropic intracellular effects (Schlessinger, 2000; Simon, 2000) . Several reports have suggested that specific aspects of EGF receptor function are independent of the intrinsic tyrosine kinase activity (Prywes et al., 1986) . Since the above results show that EGFR is necessary for TPA-and EGF-induced AP-1 activation, we ask whether the tyrosine kinase of EGFR plays a role in TPA-induced AP-1 activation. To test this idea, we observed the AP-1 activation in B82M721 cells induced by TPA. As shown in Figure 3 , TPA treatment showed similar fold induction of AP-1 activity in the B82M721 stable transfectants as compared to that in B82L stable transfectants (Figure 3 ). These data were further confirmed by time course and dose response studies (Figures 4a, b and 5b, c) . These findings indicate that the tyrosine kinase of EGFR is not required for TPAinduced AP-1 activation.
The tyrosine kinase-deficient EGFR by point mutation at Lys-721 results in deficiency of AP-1 induction in cellular response to EGF
We also test the AP-1 activation in M82M721cells and B82L cells induced by EGF. The result showed that the EGF-induced AP-1 activation was only observed in B82L cells, but not in B82M721 cells (Figure 3 ). The data from time course and dose response studies are also consistent with this observation (Figures 4c, d and 5b, c). These results support the conclusion that the tyrosine kinase-deficient EGFR by point mutation at Lys-721 results in deficiency of AP-1 induction in cellular response to EGF.
Induction of EGFR autophosphorylation at tyrosine
1173 by EGF and not TPA The results presented above indicate that tyrosine kinase of EGFR is only required for EGF-induced AP-1 activation, but not for TPA-induced AP-1 activation, and revealed that EGFR autophosphorylation at tyrosine 1173 may not play a role in TPA-induced AP-1 activity. Thus, we determined whether TPA is able to induce EGFR autophosphorylation at tyrosine 1173 . The results showed that TPA treatment had no effects on EGFR autophosphorylation at tyrosine 1173 in B82L cells, while EGF treatment resulted in a marked increase in EGFR autophosphorylation at tyrosine 1173 ( Figure 6 ). EGF-induced EGFR autophosphorylation at tyrosine 1173 was totally impaired in B82M721 cells (Figure 6 ), suggesting that Lys-721 of EGFR plays an important role in EGF-induced autophosphorylation at tyrosine 1173 of EGFR. In contrast, totally EGFR protein was expressed in a similar level in B82L and B82M721 cells, whereas B82 did not show any detectable level of EGFR ( Figure 6 ). These data support our notion that EGFR tyrosine kinase is not required for TPA-induced AP-1 activation.
Tyrosine kinase of EGFR is not required for TPA-induced ERKs activation
Previous studies reported that ERK is a major member of MAPKs involved in TPA-induced AP-1 activation ), B82L AP-1 mass1 were seeded into each well of 96-well plates. After being cultured at 371C overnight, cells were starved for 12 h by replacing medium with 0.1% FBS DMEM. Cells were then treated with TPA (10 ng/ml) or EGF (10 ng/ml). After being cultured for 24 h, the luciferase activity was measured and the results are presented as relative AP-1 activity. Each bar indicates the mean and standard deviation of four identically treated assay wells. The asterisk (*) indicates a significant difference between B82L AP-1 mass1 and B82 AP-1 mass1 (Po0.05)
Role of EGFR in TPA-and EGF-induced AP-1 activation J Li et al , Watts et al., 1998 Chen et al., 2001) . To test whether EGFR tyrosine kinase-independent activation of AP-1 by TPA is consistent with ERK activation, we compared the ERK activation by TPA among B82L, B82M721 and B82 cells. As shown in Figure 7 , TPA treatment is able to activate ERK activation in both B82L and B82M721 cells, while it did not activate ERK in B82 cells. These data suggest that ), B82L AP-1 mass1 or B82 AP-1 mass1 were seeded, cultured and starved as described for Figure 1 . For time course study, cells were treated with (a) TPA (10 ng/ml) or (c) EGF (10 ng/ml) and harvested at the time points indicated for luciferase activity assay. For dose response study, cells were treated with various doses of (b) TPA or (d) EGF and harvested at 24 h after exposure. The luciferase activity was determined as previously described (Huang et al., 1997b, c) . Results are presented as relative AP-1 activity. Each bar indicates the mean and standard deviation of four identically treated assay wells. The asterisk (*) indicates a significant difference between B82L AP-1 mass1 and B82 AP-1 mass1 (Po0.05) TPA-induced ERK activation requires EGFR, but not EGFR tyrosine kinase, which is consistent with AP-1 activation.
Discussion
EGFR was the first receptor described to possess tyrosine kinase activity (Wells, 1999) . The intrinsic tyrosine kinase activity of the EGFR has been shown to be responsible for many pleiotropic intracellular effects resulting from ligand stimulation (Wells, 1999) . In contrast, several reports have also suggested that specific aspects of EGFR function are independent of the intriasic tyrosine kinase activity (Prywes et al., 1986; Chen et al., 1987) . In the present study, we determined if EGFR and its tyrosine kinase activation are necessary for EGF-or TPA-induced AP-1 activation. We found that TPA or EGF is able to induce AP-1 activation in the cells expressing wild-type EGFR (B82L), but not in the cells devoid of the EGFR (B82). TPA-induced AP-1 activity in B82L cells is not significant different from that in B82M721. In contrast, EGF-induced AP-1 activities were observed in B82L cells, but not in B82M721 cells. Thus, we conclude that the EGFR is required for TPA-and EGF-induced AP-1 activation, whereas the tyrosine kinase of EGFR only plays a role in AP-1 activation induced by EGF, but not TPA. We also found that EGF, but not TPA, is able to induce EGFR autophosphorylation at tyrosine 1173 and this autophosphorylation at tyrosine 1173 of EGFR is dependent on tyrosine kinase of EGFR, and is critical for EGF-, but not TPA-induced AP-1 activation. EGFR is a 170 kDa single-pass transmembrane tyrosine kinase receptor. Ligand EGF binding to this receptor results in receptor dimerization autophosphorlylation, and activation of various downstream signaling molecules (Wells, 1999) . The traditional view of growth factor receptors in general is that a specific ligand directly recognizes a highly selective binding site on its cognates receptor, and thereby activates receptordependent signaling and biological responses (Gschwind et al., 2001) . Several structurally related proteins (EGF, transforming growth factor alpha, amphiregulin, betacellulin, epiregulin) are recognized as direct agonists (Carpenter, 1999; Ciardiello, 2000) . Each of these growth factors binds to the ectodomain of the EGF receptor and provokes its activation. Recently it has become apparent that the EGF receptor is also part of signaling networks activated by the stimuli that do not directly interact with the EGFR ectodomain (Carpenter, 1999) . These stimuli include G protein-coupled receptor (GPCR) ligands, other receptor tyrosine kinases (RTK) agonists, cytokines and cell adhesion elements (Carpenter, 1999; Schwartz and Baron, 1999) . In contrast, EGF receptor is a pleiotropic signaler (Wells, 1999) . The EGFR signaling may be activated by nonphysiological influences such as radiation, osmotic shock, membrane depolarization, heavy metal ions and radical-generating agents (Gschwind et al., 2001) . The integrated biological response to EGF receptor activation varies from mitogenesis to apoptosis, and from migration to differentiation. This newly discovered role of the EGF receptor as a crucial relay station between various inputs from the environment and cellular responses raises the significance of this signal-transducing receptor (Carpenter, 1999; Moghal and Stenberg, 1999) . B82 is a mouse L-cell line that is devoid of EGF receptor expression, as assessed by EGF binding as well as by RNA blot analysis (Lin et al., 1986; Chen et al., 1987) . B82L and B82M721 are transfectants of B82 cells generated by introducing wild-type human EGFR and tyrosine kinase-deficient human EGFR (contain lysine 721 to methionine 721 mutation), respectively (Chen et al., 1987) . These two variants express 350 000-450 000 human EGF receptors per cell and have similar affinity for EGF binding. Membranes prepared from untransfected B82 cells showed no EGF-dependent autophosphorylation or phosphorylation of exogenous substrates. Cell membranes from B82M721 cells exhibited neither basal-level nor EGF-stimulated protein tyrosine kinase activity (Chen et al., 1987) . These indicate that the single substitution of methionine for lysine at amino-acid position 721 of the human EGFR abolishes the intrinsic protein tyrosine kinase activity of ), B82L AP-1 mass1 or B82M721 AP-1 mass1 were seeded, cultured and starved as described for Figure 1 . For time course study, cells were treated with (a) TPA (10 ng/ml) or (c) EGF (10 ng/ml) and harvested at the time points indicated for luciferase activity assay. For dose response study, cells were treated with various doses of (b) TPA or (d) EGF and harvested at 24 h after exposure. The luciferase activity was determined as previously described (Huang et al., 1997b, c) . Results are presented as relative AP-1 activity. Each bar indicates the mean and standard deviation of four identically treated assay wells. The asterisk (*) indicates a significant difference between B82L AP-1 mass1 and B82M721 AP-1 mass1 (Po0.05) Role of EGFR in TPA-and EGF-induced AP-1 activation J Li et al the EGFR. Thus, the B82 cells and its derivatives provide an ideal model for studying the role of EGF receptor and its tyrosine kinase in EGF-and TPAinduced signaling and function. TPA has been shown to increase phosphorylation of the EGFR (Xian et al., 1995; Prenzel et al., 1999) . However, little is known whether EGF receptor is involved in TPA-induced AP-1 activation. The results from current study show that B82 cells do not have any detectable level of EGFR protein expression, whereas B82L and B82M721 express a high ) as indicated were seeded into each well of 96-well plates. After being cultured at 371C overnight, cells were starved for 12 h by replacing medium with 0.1% FBS DMEM. Cells were then treated with TPA (10 ng/ml) or EGF (10 ng/ml). After being cultured for 24 h, the luciferase activity was measured and the results are presented as relative AP-1 activity. Each bar indicates the mean and standard deviation of four identically treated assay wells. The asterisk (*) indicates a significant difference from B82 AP-1 mass1 (Po0.05)
Role of EGFR in TPA-and EGF-induced AP-1 activation J Li et al level of EGFR protein. EGF treatment results in increase in EGFR autophosphorylation in B82L cells, but not in B82 or B82M721 cells. These results are consistent with the previous report using EGF-binding affinity assay and tyrosine kinase activity assay (Chen et al., 1987) . Current studies also demonstrated that EGFR is not only required for AP-1 induction by EGF, but also is a necessary element for the initiation of signaling for TPA-induced AP-1 activation. However, the AP-1 induction by TPA is independent of EGFR tyrosine kinase and autophosphorylation at tyrosine 1173 . This conclusion is based on the finding that EGFR autophosphorylation at tyrosine 1173 is not induced by TPA treatment, and AP-1 activation in B82M721 cells is similar to that in B82L.
TPA is a highly potent tumor promoter and is widely used for the study of the mechanism of tumor promotion (Slaga et al., 1982; Huang et al., 1997e; 1999b) . AP-1 is a transcription factor comprised principally of Jun and Fos family heterodimers that binds to a consensus cis-element found on the transcription promoters of a number of genes, whose expression is induced by tumor promoters (Schaap et al., 1993) . It has been shown that AP-1 activation plays an important role in TPA-and EGF-induced tumor promotion in both in vitro and in vivo (Huang et al., 1996b; 1997a, d; Young et al., 1999) . Thus, elucidating the signaling pathways leading to AP-1 activation is a critical step for understanding the molecular mechanisms of tumor promotion induced by TPA and EGF. In the current study, we found that tyrosine kinase activation of EGFR plays a key role in AP-1 induction by EGF, but not TPA. Since overexpression of EGFR has been associated with an overall poor prognosis in patients with cancer, a number of strategies to block or downregulate EGFR have been developed to inhibit tumor proliferation and improve overall clinical outcome. These include monoclonal antibodies to the EGFR, tyrosine kinase inhibitors, ligand-linked toxins and antisense (Ciardiello, 2000; Mendelsohn and Baselga, 2000; Kong et al., 2001) . Our data show that the tyrosine kinase-deficient EGFR by mutation at Lys-721 results in deficiency of AP-1 induction by EGF. This may help us understand the mechanism of Induction of EGFR autophosphorylation at tyrosine 1173 by EGF, but not TPA. B82 and its transfectants were cultured in each well of six-well plates to 70-80% confluence with normal DMEM medium. The cell culture medium was replaced with 0.1% FBS DMEM and cultured for 33 h. Cells were incubated in serum-free MEM for 3-4 h at 371C. Cells were exposed to TPA (10 ng/ml) or EGF (10 ng/ml) for 5 or 30 min. Cells were washed once with ice-cold PBS and extracted with SDS sample buffer. Western blot was done as described in the Materials and methods section with either rabbit antiphospho-EGFR at tyrosine 1173 antibody or anti-EGFR antibody. The EGFR protein bands specifically bound to primary antibodies were detected using an anti-rabbit IgG-APlinked and by an ECF Western blotting system cancer treatment using tyrosine kinase inhibitors. It will also provide useful information for designing more effective agents for treatment of cancers. Cross-communication between diverse signaling networks is a well-established concept in the cellular stimulus-response conversion system that allows the translation of complex environmental conditions into appropriate reactions and adaptations (Gschwind et al., 2001) . Cells integrate information from distinct signaling pathways by crosstalk. EGFR is one of such crosstalk receptors (Moghal and Sternberg, 1999) . PKC is well known as a TPA receptor. It has been reported that PKC can interact with EGFR (Baker et al., 1998; Gulliford et al., 1999) . PKC has been suggested to be a positive mediator of EGFR transactivation in human embryonic kidney 293 cells (Hackel et al., 1999) . The juxtamembrane domain of EGFR serves primarily as a site for feedback attenuation by PKC and ERK (Wells, 1999; Gulliford et al., 1999) . Previous studies indicated that TPA-induced activation of AP-1 is mediated by the PKC-raf-1/MAPK kinase cascade (Troppmair et al., 1994; Young et al., 1999) . Although the detailed molecular mechanism of EGFR in TPAinduced AP-1 activation is not clear, the results from this study suggest that the crosstalk between PKC and EGFR pathways plays a role in TPA-induced AP-1 activation.
In summary, the results generated from current studies demonstrated that EGFR not only plays a role in EGF-induced AP-1 activation, but is also required for AP-1 activation induced by TPA. In contrast, the tyrosine kinase of EGFR was only involved in AP-1 activation induced by EGF, but not TPA. Consistent with AP-1 activation through an EGFR tyrosine kinase-independent manner, EGFR tyrosine kinase and EGFR autophosphorylation at tyrosine 1173 are not required for TPA-induced ERKs activation. These results help us to understand the mechanisms of EGFR in tumor formation and treatment.
Materials and methods
Cell culture and agents. Mouse fibroblast B82, B82L and B82M721, as well as their AP-1-lucifrase stable transfectants, were cultured in 10% fetal bovine serum (FBS) DMEM supplemented with 2 mm l-glutamine, and 25 mg of gentamicin/ml as described previously (Huang et al., 1996b; 1997c) . B82 is a mouse fibroblast cell line that is devoid of EGF receptor expression (Lin et al., 1986; Chen et al., 1987) . B82L and B82M721 are transfectants of B82 cells generated by introducing wild-type human EGFR and tyrosine kinase-deficient human EGFR (contain lysine 721 to methionine 721 mutation), respectively (Chen et al., 1987) . FBS was from Life Technologies, Inc.; Eagle's minimal essential medium (MEM) and Dulbecco's modified Eagle's medium (DMEM) were from Calbiochem (San Diego, CA, USA); luciferase assay substrate was from Promega; TPA was purchased from Sigma; EGF was from GIBCO BRL. The phospho-specific antibodies against phosphorylated or nonphosphorylated extracellular signal-regulated protein kinases (ERKs) were from New England Biolaboratories (Beverly, MA, USA). The mouse antiphospho-EGF receptor (Y1173) antibodies and rabbit anti-EGF receptor antibodies were purchased from Upstate biotechnology (Lake Placid, NY, USA).
Assay for AP-1 Activity in vitro. Confluent monolayers of culture cells were trypsinized, and 8 Â 10 3 viable cells suspended in 100 ml of 10% FBS DMEM were added to each well of a 96-well plate. Plates were incubated at 371C in a humidified atmosphere of 5% CO 2 . After 12-24 h, cells were starved by culturing them in 0.1% FBS medium for 24 h. Then, the cells were exposed to TPA or EGF for AP-1 induction and maintained in culture. After different periods of time cultures, the cells were extracted with lysis buffer, and luciferase activity was measured with a luminometer (Wallac 1420 Victor2 multilable counter system) after addition of 100 ml of lysis buffer for 30 min at 41C. The results are expressed as a relative AP-1 activity (Huang et al., 1996b (Huang et al., , 1997e, 1998 .
ERKs phosphorylation assay. B82 and its transfectants were cultured in monolayers in 6-well plates. After the cell density reached 70-80%, the serum in the medium was reduced from 10 to 0.1%. Cells were incubated in DMEM containing 0.1% serum and 2 mm l-glutamine for 3-4 h at 371C. Cells were then incubated with TPA (10 ng/ml) for 30 min and extracted with Tris-glycine SDS sample buffer (Invitrogen, Carlsbad, CA, USA). Western blots were performed with either phospho-specific ERKs or nonphosphorylated ERKs antibodies. The protein band specifically bound to the primary antibody was detected using an anti-rabbit IgG-AP-linked and an ECF Western blotting system (Amersham Biosciences, Piscataway, NJ, USA).
Assay for EGFR autophosphorylation at tyrosine
1173
. B82 and its transfectants were cultured in each well of six-well plates to 70-80% confluence with normal DMEM medium. The cell culture medium was replaced with 0.1% FBS DMEM with 2 mm l-glutamine and 25 mg of gentamicin and cultured for 33 h. Cells were incubated in serumfree MEM for 3-4 h at 371C. Cells were exposed to TPA (10 ng/ml) or EGF (10 ng/ml) for 5 min. Cells were washed once with ice-cold PBS and extracted with SDS-sample buffer. The cell extracts were separated on polyacrylamide-SDS gels, transferred and probed with one of the antibodies, including rabbit antiphospho-EGFR at tyrosine 1173 antibody, and anti-EGFR antibody. The EGFR phosphorylated protein and nonphosphorylated protein bands specifically bound to primary antibodies were detected using an anti-rabbit IgG-AP-linked and by an ECF Western blotting system (Amersham Biosciences, Piscataway, NJ, USA).
Statistical analysis. The significance of the difference in the AP-1 activity was determined with the Student's t-test. The results are expressed as mean Às.e.m.
Abbreviations
AP-1, activator protein-1; ERKs, extracellular signal-regulated protein kinases; MAPKs, mitogen-activated protein kinases; JNKs, c-Jun N-terminal kinases; TPA, 12-O-tetradecanoylphorbol-13-acetate; EGF, epidermal growth factor; FBS, fetal bovine serum; MEM, minimal essential medium.
